Table 1. Patient characteristics.
| Training dataset n=313 (%) | Validation dataset n=108 (%) | p-Value* | |
|---|---|---|---|
| Age at diagnosis (years) | 0.006 | ||
| Median [range] | 59 [25 – 83] | 63 [30 – 82] | |
| Sex | 0.32 | ||
| Female | 124 (40) | 37 (34) | |
| Male | 189 (60) | 71 (66) | |
| Smoking status | 0.16 | ||
| Never-smoker | 50 (16) | 11 (10) | |
| Former/current | 263 (84) | 95 (90) | |
| Missing | - | 2 | |
| Performance Status** | 0.82 | ||
| 0-1 | 247 (81) | 85 (82) | |
| 2-3 | 59 (19) | 19 (18) | |
| Missing | 7 | 4 | |
| Histology | 0.17 | ||
| Adenocarcinoma | 235 (75) | 83 (77) | |
| Squamous cell | 33 (11) | 16 (15) | |
| Other | 45 (14) | 9 (8) | |
| Primary size tumor (cm) | |||
| Median [range] | 33 [10 - 166] | 38 [11 – 54] | 0.001 |
| ≤40 | 193 (62) | 54 (52) | |
| >40 | 120 (38) | 49 (48) | |
| Missing | - | 5 | |
| Stage at diagnosis | 0.94 | ||
| I-II | 12 (4) | 4 (4) | |
| III-IV | 299 (96) | 104 (96) | |
| Missing | 2 | - | |
| Treatment | 0.010 | ||
| Carboplatin | 143 (46) | 34 (31) | |
| Cisplatin | 170 (54) | 74 (69) | |
| Number mutated/amplified genes | 0.054 | ||
| 0 | 108 (44) | 26 (32) | |
| 1-4 | 136 (56) | 55 (68) | |
| Unknown | 69 | 27 | |
| Molecular characterization | n=244 | n=81 | |
| Wild type | 108 (44) | 26 (32) | |
| ALK | 15 (6) | 3 (4) | |
| EGFR | 26 (11) | 7 (9) | |
| KRAS | 49 (20) | 12 (15) | |
| ALK/EGFR | 1 (0.4) | - | |
| ALK/KRAS | 2 (0.8) | - | |
| EGFR/KRAS | 1 (0.4) | - | |
| ALK/Other* | 2 (0.8) | - | |
| EGFR/Other* | 1 (0.4) | 1 (1) | |
| KRAS/Other* | 11 (5) | 10 (12) | |
| Other* | 28 (11) | 22 (27) |
* p-Value was calculated using χ2 for categorical variables and student test for continuous variables.
** WHO criteria.
*OTHER: HER2, MET, TP53, STK11, CDKN2, PTEN, FGFR2A, FGFR1, KDR, PI3KCA, PDPK1, NRAS.